Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Read more about Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Dosimetric impact of prostate volume change between CT-based HDR brachytherapy fractions. Read more about Dosimetric impact of prostate volume change between CT-based HDR brachytherapy fractions.
A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system. Read more about A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system.
Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Read more about Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.
A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Read more about A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer.
Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Read more about Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer.
3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Read more about 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Read more about Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Read more about Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". Read more about Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing".
